Cite
HARVARD Citation
Shi, Y. et al. (2022). Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial. Hematological oncology. 40 (5), pp. 930-940. [Online].